ESTRO 2024 - Abstract Book

S1431

Clinical - Head & neck

ESTRO 2024

0.029). Conducting a multivariate analysis revealed that induction chemotherapy improved OS (hazard ratio [HR] 0.283; 95% confidence interval [CI] 0.086-0.937, p=0.039) and DMFS (HR 0.286; 95% CI, 0.088-0.928, p=0.037).

Conclusion:

IA-CRT offered excellent LC in the patients with OCSCC. We found the addition of induction chemotherapy to IA-CRT improved OS and DMFS.

Keywords: oral cancer, chemoradiotherapy

2877

Digital Poster

Relationship of dental extraction, dosimetry, and location of ORN in head and neck cancer patients

Siona Growcott 1 , Lisa McNally 2 , John Collin 3 , Nathalie Webber 1 , Christopher Roberts 4 , Emma De Winton 4 , Sarah Hargreaves 1,5 1 Bristol Cancer Institute, Oncology, Bristol, United Kingdom. 2 Bristol Dental Hospital, Dentistry, Bristol, United Kingdom. 3 Bristol Dental Hospital, Maxillofacial Surgery, Bristol, United Kingdom. 4 Royal United Hospitals Bath, Oncology, Bath, United Kingdom. 5 University of Bristol, Bristol Dental School, Bristol, United Kingdom

Purpose/Objective: